<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109131</url>
  </required_header>
  <id_info>
    <org_study_id>IJB-BS-ODN-006</org_study_id>
    <nct_id>NCT04109131</nct_id>
  </id_info>
  <brief_title>A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours</brief_title>
  <acronym>BrainStorm</acronym>
  <official_title>A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>La Fondation contre le cancer, Belgique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Les Amis de l'Institut Bordet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Cancer, Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains&#xD;
      experimental.&#xD;
&#xD;
      Better knowledge on the evolving epidemiology and biology of BM are key elements for the&#xD;
      development of new treatment strategies and identification of promising therapeutic targets&#xD;
      for new compounds. Further biological findings may help to better understand the&#xD;
      heterogeneity between the primary tumor and the CNS metastases and to identify new targets&#xD;
      for therapy thus improving patients' outcome.&#xD;
&#xD;
      In this context, the Oncodistinct network and the Jules Bordet institute propose to build a&#xD;
      multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm. The&#xD;
      BrainStorm program will focus on patients with newly diagnosed non-CNS metastatic solid&#xD;
      tumors with high risk of developing CNS metastases and will allow building a large clinico&#xD;
      pathological database for CNS metastases including ctDNA analyzes from CSF samples.&#xD;
      Substudies will be proposed at each time-period with the final objective to develop&#xD;
      innovative treatment approaches and strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Better understanding of the epidemiology of CNS metastases from solid tumours</measure>
    <time_frame>through study completion, approximately 96 months</time_frame>
    <description>To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including:&#xD;
Time to the first CNS event&#xD;
Time to the second CNS after first treatment and subsequent CNS events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Better understanding of the epidemiology of CNS metastases from solid tumours</measure>
    <time_frame>through study completion, approximately 96 months</time_frame>
    <description>To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including::&#xD;
- Time to whole brain radiotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Better understanding of the epidemiology of CNS metastases from solid tumours</measure>
    <time_frame>through study completion, approximately 96 months</time_frame>
    <description>To collect data regarding the epidemiology of CNS metastases from solid tumours and identify risk factors for CNS metastases development, including:&#xD;
- Overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Better understand the biology of CNS metastases (brain and leptomeningeal carcinomatosis) using CSF-ctDNA as a surrogate endpoint for CNS tumour tissue DNA.</measure>
    <time_frame>through study completion, approximately 96 months</time_frame>
    <description>To collect data regarding the biology of CNS metastases by investigating on:&#xD;
Presence of CSF-ctDNA at diagnosis of CNS metastases&#xD;
Presence of plasma ctDNA at diagnosis of CNS metastases&#xD;
Molecular landscape of CSF-ctDNA, CNS metastases tumour DNA (if surgery), non-CNS tumour DNA and plasma ctDNA&#xD;
Actionable mutations in CSF-ctDNA and/or CNS metastases tumour DNA&#xD;
Potential molecular predictive biomarkers for the development of CNS metastases in plasma ctDNA and non-CNS tumour DNA&#xD;
Value of CSF-ctDNA and plasma-ctDNA for prognostic, predictive and monitoring purposes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>CNS Metastases</condition>
  <arm_group>
    <arm_group_label>CNS metastases from solid tumours</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study will be organised on three time-periods based on the time of the 1st CNS event:&#xD;
Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples collection: Plasma</intervention_name>
    <description>At baseline&#xD;
Part A:&#xD;
TNBC/ HER2+ BC: once a year&#xD;
NSCLC/SCLC: every 4 months&#xD;
Melanoma: every 6 months&#xD;
Part B:&#xD;
o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis&#xD;
Part C:&#xD;
o Every 3 months (+/- 1 month)</description>
    <arm_group_label>CNS metastases from solid tumours</arm_group_label>
    <other_name>Blood for plasma preparation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples collection: CSF</intervention_name>
    <description>Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice</description>
    <arm_group_label>CNS metastases from solid tumours</arm_group_label>
    <other_name>CSF sample</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples collection: Non-CNS Metastatic Tumour Tissue</intervention_name>
    <description>Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis</description>
    <arm_group_label>CNS metastases from solid tumours</arm_group_label>
    <other_name>Non-CNS Metastatic Tumour Tissue collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>Part A:&#xD;
Brain MRI at inclusion is allowed within 45 days before enrolment&#xD;
Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)&#xD;
Part B:&#xD;
o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis&#xD;
Part C:&#xD;
o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)</description>
    <arm_group_label>CNS metastases from solid tumours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          3. Female or Male&#xD;
&#xD;
          4. Eligible for part A: Subjects (from cohorts 1 to 5) with newly diagnosed or up to 24&#xD;
             months from diagnosis of non-CNS metastases Eligible for part B: Subjects (from&#xD;
             cohorts 1 to 7) presenting with a first CNS event and not yet enrolled in the program&#xD;
&#xD;
             Seven cohorts of subjects are defined in this prospective multicenter study:&#xD;
&#xD;
               -  Cohort 1: Triple negative breast cancer (TNBC)&#xD;
&#xD;
               -  Cohort 2: HER 2 positive breast cancer (HER2+ BC)&#xD;
&#xD;
               -  Cohort 3: Non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Cohort 4: Small cell lung cancer (SCLC)&#xD;
&#xD;
               -  Cohort 5: Melanoma&#xD;
&#xD;
               -  Cohort 6: Other solid tumours (apart from the above mentioned subtypes&#xD;
&#xD;
               -  Cohort 7: Radiologically or cytologically confirmed leptomeningeal carcinomatosis&#xD;
&#xD;
          5. Availability of either primary and/or non-CNS metastatic archival tumour tissue is&#xD;
             mandatory for inclusion.&#xD;
&#xD;
          6. Willingness to undergo lumbar puncture at diagnosis of CNS metastases unless medical&#xD;
             contra-indications&#xD;
&#xD;
          7. Predicted life expectancy &gt; 3 months.&#xD;
&#xD;
          8. Women of childbearing potential must have a negative urine pregnancy test done within&#xD;
             28 days prior to enrolment&#xD;
&#xD;
          9. Effective contraception is in place for women of childbearing potential&#xD;
&#xD;
         10. Completion of all necessary screening procedures within 28 days prior to enrolment.&#xD;
&#xD;
         11. Signed Informed Consent form (ICF) obtained prior to any study related procedure.&#xD;
&#xD;
             Inclusion criterion applicable to FRANCE only&#xD;
&#xD;
         12. Affiliated to the French Social Security System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant and/or lactating women.&#xD;
&#xD;
          2. Previous or current malignancies of other histologies within the last 5 years, with&#xD;
             the exception of in situ carcinoma of the cervix, and adequately treated basal cell or&#xD;
             squamous cell carcinoma of the skin.&#xD;
&#xD;
          3. Subject with a significant medical, neuro-psychiatric, or surgical condition,&#xD;
             currently uncontrolled by treatment, which, in the principal investigator's opinion,&#xD;
             may interfere with completion of the study.&#xD;
&#xD;
             Exclusion criterion applicable to FRANCE only&#xD;
&#xD;
          4. Vulnerable persons according to the article L.1121-6 of the Public Health Code, adults&#xD;
             who are the subject of a measure of legal protection or unable to express their&#xD;
             consent according to article L.1121-8 of the Public Health Code.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Kotecki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Kotecki</last_name>
    <phone>+322541</phone>
    <phone_ext>7366</phone_ext>
    <email>nuria.kotecki@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Delaroche</last_name>
    <phone>+322541</phone>
    <phone_ext>7358</phone_ext>
    <email>diane.delaroche@bordet.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Goblet</last_name>
      <phone>+32 2 541 30 39</phone>
      <email>Veronique.Goblet@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Florence Lefranc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Bartholomeus</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Gombos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Blondeel</last_name>
    </contact>
    <investigator>
      <last_name>François Duhoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Petre</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Luc Canon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Vansteelant</last_name>
    </contact>
    <investigator>
      <last_name>Hannelore Denys</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Cappoen</last_name>
    </contact>
    <investigator>
      <last_name>Lore Decoster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inge Wauters</last_name>
      <email>ingeborg.wauters@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Kevin Punie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Maria Barbuto</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane Holbrechts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site de Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Crasson</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Vanhaudenarde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solene Charpentier</last_name>
      <email>s-charpentier@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Cheymol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Lombardi</last_name>
      <email>LOMBARDIA@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anthony Goncalves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Blondel</last_name>
      <email>anne.blondel@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Edith Borcoman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Bridelance</last_name>
      <email>delphine.bridelance@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Florian Clatot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anais Robert</last_name>
      <email>anais.robert@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Barthelemy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Basmaison</last_name>
      <email>Basmaison.Marina@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Delord, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1445</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chouaib Mediouni</last_name>
      <email>chouaib.mediouni@lih.lu</email>
    </contact>
    <investigator>
      <last_name>Caroline Duhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

